nodes	percent_of_prediction	percent_of_DWPC	metapath
Zileuton—UGT1A9—Irinotecan—colon cancer	0.422	0.558	CbGbCtD
Zileuton—CYP2C9—Capecitabine—colon cancer	0.114	0.151	CbGbCtD
Zileuton—CYP1A2—Fluorouracil—colon cancer	0.0751	0.0994	CbGbCtD
Zileuton—CYP2C9—Fluorouracil—colon cancer	0.0677	0.0895	CbGbCtD
Zileuton—CYP3A4—Irinotecan—colon cancer	0.041	0.0543	CbGbCtD
Zileuton—CYP3A4—Vincristine—colon cancer	0.0358	0.0474	CbGbCtD
Zileuton—Chronic liver disease—Methotrexate—colon cancer	0.0167	0.148	CcSEcCtD
Zileuton—LTB4R—lymphoid tissue—colon cancer	0.00707	0.0741	CbGeAlD
Zileuton—LTB4R—bone marrow—colon cancer	0.00644	0.0675	CbGeAlD
Zileuton—LTB4R—vagina—colon cancer	0.00617	0.0646	CbGeAlD
Zileuton—UGT1A9—renal system—colon cancer	0.00573	0.06	CbGeAlD
Zileuton—LTB4R—liver—colon cancer	0.0052	0.0545	CbGeAlD
Zileuton—UGT1A9—digestive system—colon cancer	0.0047	0.0493	CbGeAlD
Zileuton—EPHX2—vagina—colon cancer	0.00454	0.0476	CbGeAlD
Zileuton—EPHX2—Metapathway biotransformation—CHST4—colon cancer	0.00424	0.132	CbGpPWpGaD
Zileuton—LTB4R—lymph node—colon cancer	0.00399	0.0418	CbGeAlD
Zileuton—ALOX5—smooth muscle tissue—colon cancer	0.0039	0.0409	CbGeAlD
Zileuton—EPHX2—liver—colon cancer	0.00383	0.0401	CbGeAlD
Zileuton—PTGS1—endothelium—colon cancer	0.00362	0.0379	CbGeAlD
Zileuton—UGT1A9—liver—colon cancer	0.0035	0.0367	CbGeAlD
Zileuton—PTGS1—blood vessel—colon cancer	0.00334	0.035	CbGeAlD
Zileuton—ALOX5—lymphoid tissue—colon cancer	0.00312	0.0327	CbGeAlD
Zileuton—ALOX5—digestive system—colon cancer	0.00308	0.0323	CbGeAlD
Zileuton—Tiaprofenic acid—PTGS2—colon cancer	0.00304	1	CrCbGaD
Zileuton—EPHX2—lymph node—colon cancer	0.00293	0.0308	CbGeAlD
Zileuton—ALOX5—bone marrow—colon cancer	0.00284	0.0297	CbGeAlD
Zileuton—Hyperbilirubinaemia—Irinotecan—colon cancer	0.00266	0.0235	CcSEcCtD
Zileuton—Pharyngolaryngeal pain—Capecitabine—colon cancer	0.0024	0.0211	CcSEcCtD
Zileuton—Laryngeal pain—Capecitabine—colon cancer	0.00238	0.0209	CcSEcCtD
Zileuton—ALOX5—liver—colon cancer	0.00229	0.024	CbGeAlD
Zileuton—Hepatotoxicity—Capecitabine—colon cancer	0.0021	0.0185	CcSEcCtD
Zileuton—EPHX2—Metapathway biotransformation—CHST5—colon cancer	0.00194	0.0604	CbGpPWpGaD
Zileuton—Hyperbilirubinaemia—Capecitabine—colon cancer	0.00178	0.0157	CcSEcCtD
Zileuton—Liver disorder—Methotrexate—colon cancer	0.00177	0.0156	CcSEcCtD
Zileuton—ALOX5—lymph node—colon cancer	0.00176	0.0184	CbGeAlD
Zileuton—CYP1A2—renal system—colon cancer	0.00174	0.0182	CbGeAlD
Zileuton—Neck pain—Capecitabine—colon cancer	0.00164	0.0145	CcSEcCtD
Zileuton—PTGS1—epithelium—colon cancer	0.00162	0.017	CbGeAlD
Zileuton—PTGS1—smooth muscle tissue—colon cancer	0.00156	0.0164	CbGeAlD
Zileuton—Hepatotoxicity—Methotrexate—colon cancer	0.00156	0.0138	CcSEcCtD
Zileuton—PTGS1—renal system—colon cancer	0.00151	0.0158	CbGeAlD
Zileuton—CYP1A2—digestive system—colon cancer	0.00143	0.0149	CbGeAlD
Zileuton—Upper respiratory tract infection—Irinotecan—colon cancer	0.00141	0.0124	CcSEcCtD
Zileuton—Sleep disorder—Capecitabine—colon cancer	0.00136	0.012	CcSEcCtD
Zileuton—CYP2C9—digestive system—colon cancer	0.00135	0.0142	CbGeAlD
Zileuton—Upper respiratory tract infection—Fluorouracil—colon cancer	0.00135	0.0119	CcSEcCtD
Zileuton—Hyperbilirubinaemia—Methotrexate—colon cancer	0.00133	0.0117	CcSEcCtD
Zileuton—Jaundice—Irinotecan—colon cancer	0.00132	0.0116	CcSEcCtD
Zileuton—Conjunctivitis—Fluorouracil—colon cancer	0.00126	0.0111	CcSEcCtD
Zileuton—Urinary tract infection—Fluorouracil—colon cancer	0.00126	0.0111	CcSEcCtD
Zileuton—CYP3A4—renal system—colon cancer	0.00126	0.0132	CbGeAlD
Zileuton—UGT1A9—Metapathway biotransformation—CHST4—colon cancer	0.00125	0.0389	CbGpPWpGaD
Zileuton—PTGS1—digestive system—colon cancer	0.00124	0.013	CbGeAlD
Zileuton—Sinusitis—Fluorouracil—colon cancer	0.00122	0.0107	CcSEcCtD
Zileuton—Vaginal inflammation—Methotrexate—colon cancer	0.00121	0.0106	CcSEcCtD
Zileuton—Vaginal infection—Methotrexate—colon cancer	0.00114	0.01	CcSEcCtD
Zileuton—PTGS1—vagina—colon cancer	0.00109	0.0114	CbGeAlD
Zileuton—Abdominal pain upper—Capecitabine—colon cancer	0.00107	0.00947	CcSEcCtD
Zileuton—CYP1A2—liver—colon cancer	0.00106	0.0111	CbGeAlD
Zileuton—Flatulence—Irinotecan—colon cancer	0.00104	0.00919	CcSEcCtD
Zileuton—CYP3A4—digestive system—colon cancer	0.00103	0.0108	CbGeAlD
Zileuton—Lymphadenopathy—Methotrexate—colon cancer	0.00103	0.00904	CcSEcCtD
Zileuton—CYP2C9—liver—colon cancer	0.00101	0.0106	CbGeAlD
Zileuton—Ill-defined disorder—Irinotecan—colon cancer	0.000982	0.00865	CcSEcCtD
Zileuton—Malaise—Irinotecan—colon cancer	0.000954	0.00841	CcSEcCtD
Zileuton—Upper respiratory tract infection—Capecitabine—colon cancer	0.000945	0.00833	CcSEcCtD
Zileuton—Myalgia—Vincristine—colon cancer	0.000925	0.00815	CcSEcCtD
Zileuton—Discomfort—Irinotecan—colon cancer	0.00089	0.00784	CcSEcCtD
Zileuton—Jaundice—Capecitabine—colon cancer	0.000883	0.00779	CcSEcCtD
Zileuton—Conjunctivitis—Capecitabine—colon cancer	0.000881	0.00776	CcSEcCtD
Zileuton—Urinary tract infection—Capecitabine—colon cancer	0.000881	0.00776	CcSEcCtD
Zileuton—Myalgia—Fluorouracil—colon cancer	0.000863	0.0076	CcSEcCtD
Zileuton—Chest pain—Fluorouracil—colon cancer	0.000863	0.0076	CcSEcCtD
Zileuton—Discomfort—Fluorouracil—colon cancer	0.000852	0.00751	CcSEcCtD
Zileuton—UGT1A9—Irinotecan Pathway—APC—colon cancer	0.000827	0.0257	CbGpPWpGaD
Zileuton—Hepatitis—Capecitabine—colon cancer	0.000813	0.00717	CcSEcCtD
Zileuton—Musculoskeletal discomfort—Vincristine—colon cancer	0.000808	0.00712	CcSEcCtD
Zileuton—Insomnia—Vincristine—colon cancer	0.000802	0.00707	CcSEcCtD
Zileuton—Insomnia—Irinotecan—colon cancer	0.000781	0.00688	CcSEcCtD
Zileuton—CYP3A4—liver—colon cancer	0.000769	0.00806	CbGeAlD
Zileuton—Somnolence—Irinotecan—colon cancer	0.000768	0.00677	CcSEcCtD
Zileuton—ALOX5—Eicosanoid Synthesis—PTGS2—colon cancer	0.000767	0.0238	CbGpPWpGaD
Zileuton—EPHX2—Arachidonic acid metabolism—PTGS2—colon cancer	0.000766	0.0238	CbGpPWpGaD
Zileuton—Gastrointestinal disorder—Vincristine—colon cancer	0.000765	0.00675	CcSEcCtD
Zileuton—Dyspepsia—Irinotecan—colon cancer	0.00076	0.0067	CcSEcCtD
Zileuton—Constipation—Vincristine—colon cancer	0.000758	0.00668	CcSEcCtD
Zileuton—Pain—Vincristine—colon cancer	0.000758	0.00668	CcSEcCtD
Zileuton—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000753	0.00664	CcSEcCtD
Zileuton—Insomnia—Fluorouracil—colon cancer	0.000748	0.00659	CcSEcCtD
Zileuton—Gastrointestinal disorder—Irinotecan—colon cancer	0.000745	0.00657	CcSEcCtD
Zileuton—Constipation—Irinotecan—colon cancer	0.000738	0.00651	CcSEcCtD
Zileuton—Pain—Irinotecan—colon cancer	0.000738	0.00651	CcSEcCtD
Zileuton—Somnolence—Fluorouracil—colon cancer	0.000735	0.00648	CcSEcCtD
Zileuton—Dyspepsia—Fluorouracil—colon cancer	0.000728	0.00642	CcSEcCtD
Zileuton—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000714	0.00629	CcSEcCtD
Zileuton—Feeling abnormal—Irinotecan—colon cancer	0.000712	0.00627	CcSEcCtD
Zileuton—Pain—Fluorouracil—colon cancer	0.000707	0.00623	CcSEcCtD
Zileuton—PTGS1—lymph node—colon cancer	0.000706	0.0074	CbGeAlD
Zileuton—Upper respiratory tract infection—Methotrexate—colon cancer	0.000703	0.0062	CcSEcCtD
Zileuton—Body temperature increased—Vincristine—colon cancer	0.000701	0.00618	CcSEcCtD
Zileuton—Flatulence—Capecitabine—colon cancer	0.000698	0.00615	CcSEcCtD
Zileuton—PTGS1—Overview of nanoparticle effects—BAX—colon cancer	0.000693	0.0215	CbGpPWpGaD
Zileuton—Body temperature increased—Irinotecan—colon cancer	0.000683	0.00602	CcSEcCtD
Zileuton—Feeling abnormal—Fluorouracil—colon cancer	0.000682	0.00601	CcSEcCtD
Zileuton—Ill-defined disorder—Capecitabine—colon cancer	0.000657	0.00579	CcSEcCtD
Zileuton—Urticaria—Fluorouracil—colon cancer	0.000657	0.00579	CcSEcCtD
Zileuton—Conjunctivitis—Methotrexate—colon cancer	0.000656	0.00578	CcSEcCtD
Zileuton—Body temperature increased—Fluorouracil—colon cancer	0.000654	0.00576	CcSEcCtD
Zileuton—Hypersensitivity—Vincristine—colon cancer	0.000653	0.00576	CcSEcCtD
Zileuton—Malaise—Capecitabine—colon cancer	0.000639	0.00563	CcSEcCtD
Zileuton—Hypersensitivity—Irinotecan—colon cancer	0.000636	0.00561	CcSEcCtD
Zileuton—Hypersensitivity—Fluorouracil—colon cancer	0.000609	0.00537	CcSEcCtD
Zileuton—Diarrhoea—Vincristine—colon cancer	0.000607	0.00535	CcSEcCtD
Zileuton—Hepatitis—Methotrexate—colon cancer	0.000606	0.00534	CcSEcCtD
Zileuton—Chest pain—Capecitabine—colon cancer	0.000603	0.00531	CcSEcCtD
Zileuton—Arthralgia—Capecitabine—colon cancer	0.000603	0.00531	CcSEcCtD
Zileuton—Myalgia—Capecitabine—colon cancer	0.000603	0.00531	CcSEcCtD
Zileuton—Discomfort—Capecitabine—colon cancer	0.000596	0.00525	CcSEcCtD
Zileuton—UGT1A9—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000592	0.0184	CbGpPWpGaD
Zileuton—Diarrhoea—Irinotecan—colon cancer	0.000591	0.00521	CcSEcCtD
Zileuton—Dizziness—Vincristine—colon cancer	0.000586	0.00517	CcSEcCtD
Zileuton—Pruritus—Fluorouracil—colon cancer	0.000585	0.00516	CcSEcCtD
Zileuton—UGT1A9—Metapathway biotransformation—CHST5—colon cancer	0.000575	0.0179	CbGpPWpGaD
Zileuton—Dizziness—Irinotecan—colon cancer	0.000571	0.00503	CcSEcCtD
Zileuton—Diarrhoea—Fluorouracil—colon cancer	0.000566	0.00499	CcSEcCtD
Zileuton—Vomiting—Vincristine—colon cancer	0.000564	0.00497	CcSEcCtD
Zileuton—Rash—Vincristine—colon cancer	0.000559	0.00493	CcSEcCtD
Zileuton—Dermatitis—Vincristine—colon cancer	0.000559	0.00492	CcSEcCtD
Zileuton—EPHX2—Metabolism—CA7—colon cancer	0.000557	0.0173	CbGpPWpGaD
Zileuton—Headache—Vincristine—colon cancer	0.000555	0.0049	CcSEcCtD
Zileuton—Vomiting—Irinotecan—colon cancer	0.000549	0.00484	CcSEcCtD
Zileuton—Dizziness—Fluorouracil—colon cancer	0.000547	0.00482	CcSEcCtD
Zileuton—Rash—Irinotecan—colon cancer	0.000544	0.0048	CcSEcCtD
Zileuton—Dermatitis—Irinotecan—colon cancer	0.000544	0.00479	CcSEcCtD
Zileuton—Headache—Irinotecan—colon cancer	0.000541	0.00477	CcSEcCtD
Zileuton—CYP2C9—Metapathway biotransformation—CHST4—colon cancer	0.000537	0.0167	CbGpPWpGaD
Zileuton—Nausea—Vincristine—colon cancer	0.000527	0.00464	CcSEcCtD
Zileuton—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000527	0.00464	CcSEcCtD
Zileuton—Vomiting—Fluorouracil—colon cancer	0.000526	0.00463	CcSEcCtD
Zileuton—Insomnia—Capecitabine—colon cancer	0.000523	0.00461	CcSEcCtD
Zileuton—Rash—Fluorouracil—colon cancer	0.000521	0.0046	CcSEcCtD
Zileuton—Dermatitis—Fluorouracil—colon cancer	0.000521	0.00459	CcSEcCtD
Zileuton—Headache—Fluorouracil—colon cancer	0.000518	0.00457	CcSEcCtD
Zileuton—Nausea—Irinotecan—colon cancer	0.000513	0.00452	CcSEcCtD
Zileuton—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—colon cancer	0.000512	0.0159	CbGpPWpGaD
Zileuton—Dyspepsia—Capecitabine—colon cancer	0.000509	0.00448	CcSEcCtD
Zileuton—CYP3A4—Codeine and Morphine Metabolism—ABCB1—colon cancer	0.000507	0.0158	CbGpPWpGaD
Zileuton—Gastrointestinal disorder—Capecitabine—colon cancer	0.000499	0.0044	CcSEcCtD
Zileuton—Constipation—Capecitabine—colon cancer	0.000494	0.00436	CcSEcCtD
Zileuton—Pain—Capecitabine—colon cancer	0.000494	0.00436	CcSEcCtD
Zileuton—Nausea—Fluorouracil—colon cancer	0.000491	0.00433	CcSEcCtD
Zileuton—Ill-defined disorder—Methotrexate—colon cancer	0.000489	0.00431	CcSEcCtD
Zileuton—Feeling abnormal—Capecitabine—colon cancer	0.000476	0.0042	CcSEcCtD
Zileuton—Malaise—Methotrexate—colon cancer	0.000475	0.00419	CcSEcCtD
Zileuton—Urticaria—Capecitabine—colon cancer	0.000459	0.00405	CcSEcCtD
Zileuton—CYP1A2—Metapathway biotransformation—CHST4—colon cancer	0.000459	0.0143	CbGpPWpGaD
Zileuton—Body temperature increased—Capecitabine—colon cancer	0.000457	0.00403	CcSEcCtD
Zileuton—Chest pain—Methotrexate—colon cancer	0.000449	0.00396	CcSEcCtD
Zileuton—Myalgia—Methotrexate—colon cancer	0.000449	0.00396	CcSEcCtD
Zileuton—Arthralgia—Methotrexate—colon cancer	0.000449	0.00396	CcSEcCtD
Zileuton—Discomfort—Methotrexate—colon cancer	0.000443	0.00391	CcSEcCtD
Zileuton—ALOX5—Arachidonic acid metabolism—PTGS2—colon cancer	0.000426	0.0132	CbGpPWpGaD
Zileuton—Hypersensitivity—Capecitabine—colon cancer	0.000426	0.00375	CcSEcCtD
Zileuton—UGT1A9—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.000419	0.013	CbGpPWpGaD
Zileuton—Pruritus—Capecitabine—colon cancer	0.000409	0.0036	CcSEcCtD
Zileuton—PTGS1—Overview of nanoparticle effects—PTGS2—colon cancer	0.000401	0.0125	CbGpPWpGaD
Zileuton—Diarrhoea—Capecitabine—colon cancer	0.000395	0.00349	CcSEcCtD
Zileuton—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000392	0.00345	CcSEcCtD
Zileuton—Insomnia—Methotrexate—colon cancer	0.000389	0.00343	CcSEcCtD
Zileuton—LTB4R—Spinal Cord Injury—PTGS2—colon cancer	0.000385	0.012	CbGpPWpGaD
Zileuton—Somnolence—Methotrexate—colon cancer	0.000382	0.00337	CcSEcCtD
Zileuton—Dizziness—Capecitabine—colon cancer	0.000382	0.00337	CcSEcCtD
Zileuton—Dyspepsia—Methotrexate—colon cancer	0.000379	0.00334	CcSEcCtD
Zileuton—Gastrointestinal disorder—Methotrexate—colon cancer	0.000371	0.00327	CcSEcCtD
Zileuton—Pain—Methotrexate—colon cancer	0.000368	0.00324	CcSEcCtD
Zileuton—Vomiting—Capecitabine—colon cancer	0.000367	0.00324	CcSEcCtD
Zileuton—Rash—Capecitabine—colon cancer	0.000364	0.00321	CcSEcCtD
Zileuton—Dermatitis—Capecitabine—colon cancer	0.000364	0.00321	CcSEcCtD
Zileuton—Headache—Capecitabine—colon cancer	0.000362	0.00319	CcSEcCtD
Zileuton—LTB4R—Spinal Cord Injury—CASP3—colon cancer	0.000358	0.0111	CbGpPWpGaD
Zileuton—Feeling abnormal—Methotrexate—colon cancer	0.000355	0.00312	CcSEcCtD
Zileuton—CYP3A4—Metapathway biotransformation—CHST4—colon cancer	0.000354	0.011	CbGpPWpGaD
Zileuton—LTB4R—Spinal Cord Injury—CCND1—colon cancer	0.000348	0.0108	CbGpPWpGaD
Zileuton—UGT1A9—PPAR Alpha Pathway—CCND1—colon cancer	0.000346	0.0107	CbGpPWpGaD
Zileuton—Nausea—Capecitabine—colon cancer	0.000343	0.00303	CcSEcCtD
Zileuton—Urticaria—Methotrexate—colon cancer	0.000342	0.00301	CcSEcCtD
Zileuton—Body temperature increased—Methotrexate—colon cancer	0.00034	0.003	CcSEcCtD
Zileuton—EPHX2—Metabolism—CHST5—colon cancer	0.000337	0.0105	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—ODC1—colon cancer	0.000337	0.0105	CbGpPWpGaD
Zileuton—PTGS1—Eicosanoid Synthesis—PTGS2—colon cancer	0.000332	0.0103	CbGpPWpGaD
Zileuton—Hypersensitivity—Methotrexate—colon cancer	0.000317	0.00279	CcSEcCtD
Zileuton—ALOX5—Metabolism—CA7—colon cancer	0.00031	0.00962	CbGpPWpGaD
Zileuton—Pruritus—Methotrexate—colon cancer	0.000304	0.00268	CcSEcCtD
Zileuton—LTB4R—Signaling Pathways—DLC1—colon cancer	0.0003	0.00932	CbGpPWpGaD
Zileuton—Diarrhoea—Methotrexate—colon cancer	0.000294	0.00259	CcSEcCtD
Zileuton—Dizziness—Methotrexate—colon cancer	0.000284	0.00251	CcSEcCtD
Zileuton—LTB4R—Signaling Pathways—LGR5—colon cancer	0.000282	0.00876	CbGpPWpGaD
Zileuton—LTB4R—Spinal Cord Injury—MYC—colon cancer	0.000279	0.00868	CbGpPWpGaD
Zileuton—LTB4R—Spinal Cord Injury—TGFB1—colon cancer	0.000279	0.00866	CbGpPWpGaD
Zileuton—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—colon cancer	0.000278	0.00864	CbGpPWpGaD
Zileuton—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.000278	0.00862	CbGpPWpGaD
Zileuton—UGT1A9—PPAR Alpha Pathway—MYC—colon cancer	0.000277	0.00862	CbGpPWpGaD
Zileuton—Vomiting—Methotrexate—colon cancer	0.000274	0.00241	CcSEcCtD
Zileuton—LTB4R—Spinal Cord Injury—EGFR—colon cancer	0.000273	0.00849	CbGpPWpGaD
Zileuton—Rash—Methotrexate—colon cancer	0.000271	0.00239	CcSEcCtD
Zileuton—ALOX5—Selenium Micronutrient Network—PTGS2—colon cancer	0.000271	0.00843	CbGpPWpGaD
Zileuton—Dermatitis—Methotrexate—colon cancer	0.000271	0.00239	CcSEcCtD
Zileuton—Headache—Methotrexate—colon cancer	0.00027	0.00238	CcSEcCtD
Zileuton—Nausea—Methotrexate—colon cancer	0.000256	0.00225	CcSEcCtD
Zileuton—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000254	0.00788	CbGpPWpGaD
Zileuton—CYP2C9—Metapathway biotransformation—CHST5—colon cancer	0.000247	0.00766	CbGpPWpGaD
Zileuton—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000242	0.00751	CbGpPWpGaD
Zileuton—CYP3A4—Irinotecan Pathway—APC—colon cancer	0.000234	0.00726	CbGpPWpGaD
Zileuton—LTB4R—Spinal Cord Injury—TP53—colon cancer	0.000229	0.00713	CbGpPWpGaD
Zileuton—CYP1A2—Metapathway biotransformation—CHST5—colon cancer	0.000211	0.00655	CbGpPWpGaD
Zileuton—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000207	0.00642	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—AXIN2—colon cancer	0.000203	0.0063	CbGpPWpGaD
Zileuton—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	0.000202	0.00626	CbGpPWpGaD
Zileuton—UGT1A9—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	0.000196	0.00609	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—ODC1—colon cancer	0.000188	0.00583	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—CHST5—colon cancer	0.000188	0.00583	CbGpPWpGaD
Zileuton—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—colon cancer	0.000186	0.00577	CbGpPWpGaD
Zileuton—PTGS1—Arachidonic acid metabolism—PTGS2—colon cancer	0.000185	0.00574	CbGpPWpGaD
Zileuton—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	0.000175	0.00545	CbGpPWpGaD
Zileuton—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	0.000172	0.00534	CbGpPWpGaD
Zileuton—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—colon cancer	0.000169	0.00526	CbGpPWpGaD
Zileuton—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000168	0.00523	CbGpPWpGaD
Zileuton—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000167	0.0052	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—CA7—colon cancer	0.000165	0.00512	CbGpPWpGaD
Zileuton—LTB4R—G alpha (q) signalling events—PIK3CA—colon cancer	0.000164	0.0051	CbGpPWpGaD
Zileuton—CYP3A4—Metapathway biotransformation—CHST5—colon cancer	0.000163	0.00505	CbGpPWpGaD
Zileuton—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—colon cancer	0.00016	0.00496	CbGpPWpGaD
Zileuton—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000159	0.00495	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor Pathway—BAX—colon cancer	0.000153	0.00477	CbGpPWpGaD
Zileuton—UGT1A9—PPARA activates gene expression—PPARG—colon cancer	0.000153	0.00477	CbGpPWpGaD
Zileuton—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—colon cancer	0.00015	0.00466	CbGpPWpGaD
Zileuton—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—colon cancer	0.000147	0.00456	CbGpPWpGaD
Zileuton—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000144	0.00447	CbGpPWpGaD
Zileuton—EPHX2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.000139	0.00433	CbGpPWpGaD
Zileuton—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—colon cancer	0.000136	0.00422	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—CA7—colon cancer	0.000134	0.00417	CbGpPWpGaD
Zileuton—PTGS1—Selenium Micronutrient Network—PTGS2—colon cancer	0.000118	0.00365	CbGpPWpGaD
Zileuton—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000111	0.00345	CbGpPWpGaD
Zileuton—EPHX2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	0.00011	0.0034	CbGpPWpGaD
Zileuton—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	0.000103	0.00321	CbGpPWpGaD
Zileuton—UGT1A9—PPARA activates gene expression—EP300—colon cancer	0.0001	0.00312	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—ODC1—colon cancer	9.98e-05	0.0031	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—CHST5—colon cancer	9.98e-05	0.0031	CbGpPWpGaD
Zileuton—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	9.82e-05	0.00305	CbGpPWpGaD
Zileuton—CYP2C9—Arachidonic acid metabolism—PTGS2—colon cancer	9.72e-05	0.00302	CbGpPWpGaD
Zileuton—EPHX2—Metabolism of lipids and lipoproteins—EP300—colon cancer	9.11e-05	0.00283	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—ABCB1—colon cancer	8.91e-05	0.00277	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—colon cancer	8.87e-05	0.00276	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—TYMS—colon cancer	8.75e-05	0.00272	CbGpPWpGaD
Zileuton—CYP1A2—Arachidonic acid metabolism—PTGS2—colon cancer	8.3e-05	0.00258	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—CHST5—colon cancer	8.13e-05	0.00253	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—ODC1—colon cancer	8.13e-05	0.00253	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	7.76e-05	0.00241	CbGpPWpGaD
Zileuton—ALOX5—Metabolism of lipids and lipoproteins—PPARG—colon cancer	7.74e-05	0.00241	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—EP300—colon cancer	7.38e-05	0.00229	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	7.38e-05	0.00229	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—SRC—colon cancer	7.18e-05	0.00223	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	7.18e-05	0.00223	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—CA7—colon cancer	7.06e-05	0.00219	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	6.99e-05	0.00217	CbGpPWpGaD
Zileuton—UGT1A9—NRF2 pathway—TGFB1—colon cancer	6.95e-05	0.00216	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—colon cancer	6.91e-05	0.00215	CbGpPWpGaD
Zileuton—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	6.77e-05	0.0021	CbGpPWpGaD
Zileuton—EPHX2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	6.74e-05	0.00209	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—MYC—colon cancer	6.43e-05	0.002	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	6.42e-05	0.00199	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	6.29e-05	0.00196	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	6.29e-05	0.00196	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—PPARG—colon cancer	6.2e-05	0.00193	CbGpPWpGaD
Zileuton—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	6.09e-05	0.00189	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—CA7—colon cancer	6.03e-05	0.00187	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	5.94e-05	0.00185	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—FGFR3—colon cancer	5.85e-05	0.00182	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—APC—colon cancer	5.37e-05	0.00167	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—NRAS—colon cancer	5.37e-05	0.00167	CbGpPWpGaD
Zileuton—ALOX5—Metabolism of lipids and lipoproteins—EP300—colon cancer	5.07e-05	0.00157	CbGpPWpGaD
Zileuton—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	5.05e-05	0.00157	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—BRAF—colon cancer	5.05e-05	0.00157	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—ABCB1—colon cancer	4.96e-05	0.00154	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—EGFR—colon cancer	4.89e-05	0.00152	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—PTGS2—colon cancer	4.88e-05	0.00152	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—TYMS—colon cancer	4.87e-05	0.00151	CbGpPWpGaD
Zileuton—LTB4R—GPCR downstream signaling—PIK3CA—colon cancer	4.68e-05	0.00145	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—CA7—colon cancer	4.65e-05	0.00145	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—KRAS—colon cancer	4.62e-05	0.00144	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—CHST5—colon cancer	4.28e-05	0.00133	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—ODC1—colon cancer	4.28e-05	0.00133	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—PIK3CA—colon cancer	4.25e-05	0.00132	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	4.12e-05	0.00128	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—EP300—colon cancer	4.06e-05	0.00126	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—HRAS—colon cancer	3.93e-05	0.00122	CbGpPWpGaD
Zileuton—LTB4R—GPCR downstream signaling—AKT1—colon cancer	3.82e-05	0.00119	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—CASP3—colon cancer	3.79e-05	0.00118	CbGpPWpGaD
Zileuton—ALOX5—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.75e-05	0.00116	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—CCND1—colon cancer	3.68e-05	0.00115	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—ODC1—colon cancer	3.65e-05	0.00114	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—CHST5—colon cancer	3.65e-05	0.00114	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—CTNNB1—colon cancer	3.65e-05	0.00113	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—CDKN1A—colon cancer	3.56e-05	0.00111	CbGpPWpGaD
Zileuton—LTB4R—Signaling by GPCR—AKT1—colon cancer	3.47e-05	0.00108	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—PPARG—colon cancer	3.45e-05	0.00107	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—EP300—colon cancer	3.39e-05	0.00105	CbGpPWpGaD
Zileuton—PTGS1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.36e-05	0.00104	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—SRC—colon cancer	3.3e-05	0.00102	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.24e-05	0.00101	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—VEGFA—colon cancer	3.21e-05	0.000998	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—NRAS—colon cancer	3.17e-05	0.000986	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—PIK3CA—colon cancer	3e-05	0.000932	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—MYC—colon cancer	2.96e-05	0.000918	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—TGFB1—colon cancer	2.95e-05	0.000916	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—EGFR—colon cancer	2.89e-05	0.000898	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—ODC1—colon cancer	2.82e-05	0.000876	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—CHST5—colon cancer	2.82e-05	0.000876	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—KRAS—colon cancer	2.73e-05	0.000849	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—PTGS2—colon cancer	2.71e-05	0.000843	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.69e-05	0.000837	CbGpPWpGaD
Zileuton—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.64e-05	0.000821	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—ABCB1—colon cancer	2.64e-05	0.000819	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—TYMS—colon cancer	2.59e-05	0.000805	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—PIK3CA—colon cancer	2.51e-05	0.00078	CbGpPWpGaD
Zileuton—EPHX2—Metabolism—AKT1—colon cancer	2.45e-05	0.000762	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—TP53—colon cancer	2.43e-05	0.000754	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—HRAS—colon cancer	2.32e-05	0.000721	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—EP300—colon cancer	2.26e-05	0.000701	CbGpPWpGaD
Zileuton—PTGS1—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.2e-05	0.000683	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—ABCB1—colon cancer	2.15e-05	0.000668	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—TYMS—colon cancer	2.11e-05	0.000656	CbGpPWpGaD
Zileuton—LTB4R—Signaling Pathways—AKT1—colon cancer	2.05e-05	0.000637	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.99e-05	0.00062	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—PPARG—colon cancer	1.83e-05	0.00057	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.77e-05	0.000549	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—PIK3CA—colon cancer	1.67e-05	0.000519	CbGpPWpGaD
Zileuton—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.62e-05	0.000505	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.51e-05	0.000469	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—PPARG—colon cancer	1.5e-05	0.000465	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—PTGS2—colon cancer	1.44e-05	0.000448	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.39e-05	0.000432	CbGpPWpGaD
Zileuton—ALOX5—Metabolism—AKT1—colon cancer	1.36e-05	0.000424	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—EP300—colon cancer	1.2e-05	0.000373	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.19e-05	0.000369	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—PTGS2—colon cancer	1.18e-05	0.000366	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.15e-05	0.000359	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—ABCB1—colon cancer	1.13e-05	0.000351	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—TYMS—colon cancer	1.11e-05	0.000345	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	9.87e-06	0.000307	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—EP300—colon cancer	9.78e-06	0.000304	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—ABCB1—colon cancer	9.66e-06	0.0003	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—TYMS—colon cancer	9.48e-06	0.000295	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—PIK3CA—colon cancer	8.88e-06	0.000276	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	8.54e-06	0.000265	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—PPARG—colon cancer	7.86e-06	0.000244	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—ABCB1—colon cancer	7.45e-06	0.000232	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—TYMS—colon cancer	7.32e-06	0.000227	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	7.3e-06	0.000227	CbGpPWpGaD
Zileuton—UGT1A9—Metabolism—AKT1—colon cancer	7.25e-06	0.000225	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—PIK3CA—colon cancer	7.24e-06	0.000225	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—PPARG—colon cancer	6.72e-06	0.000209	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—PTGS2—colon cancer	6.18e-06	0.000192	CbGpPWpGaD
Zileuton—PTGS1—Metabolism—AKT1—colon cancer	5.91e-06	0.000184	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—PTGS2—colon cancer	5.28e-06	0.000164	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—PPARG—colon cancer	5.18e-06	0.000161	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—EP300—colon cancer	5.14e-06	0.00016	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—EP300—colon cancer	4.39e-06	0.000137	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—PTGS2—colon cancer	4.08e-06	0.000127	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—PIK3CA—colon cancer	3.8e-06	0.000118	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—EP300—colon cancer	3.39e-06	0.000105	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—PIK3CA—colon cancer	3.25e-06	0.000101	CbGpPWpGaD
Zileuton—CYP2C9—Metabolism—AKT1—colon cancer	3.11e-06	9.66e-05	CbGpPWpGaD
Zileuton—CYP1A2—Metabolism—AKT1—colon cancer	2.66e-06	8.25e-05	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—PIK3CA—colon cancer	2.51e-06	7.8e-05	CbGpPWpGaD
Zileuton—CYP3A4—Metabolism—AKT1—colon cancer	2.05e-06	6.37e-05	CbGpPWpGaD
